Investors must take note of Allogene Therapeutics Inc’s (ALLO) performance last week, which was 13.89%.

On Monday, Allogene Therapeutics Inc (NASDAQ: ALLO) opened lower -5.96% from the last session, before settling in for the closing price of $2.18. Price fluctuations for ALLO have ranged from $1.32 to $5.78 over the past 52 weeks.

Annual sales at Healthcare sector company slipped by -34.74% over the past five years. Company’s average yearly earnings per share was noted 36.24% at the time writing. With a float of $134.60 million, this company’s outstanding shares have now reached $209.50 million.

Let’s look at the performance matrix of the company that is accounted for 233 employees. In terms of profitability, gross margin is -143760.47%, operating margin of -650195.35%, and the pretax margin is -659137.21%.

Allogene Therapeutics Inc (ALLO) Insider and Institutional Ownership

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Allogene Therapeutics Inc is 35.83%, while institutional ownership is 65.94%. The most recent insider transaction that took place on Feb 18 ’25, was worth 32,351. In this transaction Director of this company sold 13,313 shares at a rate of $2.43, taking the stock ownership to the 144,316 shares. Before that another transaction happened on Feb 18 ’25, when Company’s Director proposed sale 13,313 for $2.43, making the entire transaction worth $32,329.

Allogene Therapeutics Inc (ALLO) Latest Financial update

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 36.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.40% during the next five years compared to 22.18% growth over the previous five years of trading.

Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators

Check out the current performance indicators for Allogene Therapeutics Inc (ALLO). In the past quarter, the stock posted a quick ratio of 9.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10745.75.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.56, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.35 in one year’s time.

Technical Analysis of Allogene Therapeutics Inc (ALLO)

Allogene Therapeutics Inc (NASDAQ: ALLO) saw its 5-day average volume 3.36 million, a negative change from its year-to-date volume of 6.2 million. As of the previous 9 days, the stock’s Stochastic %D was 62.43%. Additionally, its Average True Range was 0.27.

During the past 100 days, Allogene Therapeutics Inc’s (ALLO) raw stochastic average was set at 29.67%, which indicates a significant increase from 17.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 95.45% in the past 14 days, which was lower than the 113.49% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $1.96, while its 200-day Moving Average is $2.41. Nevertheless, the first resistance level for the watch stands at $2.17 in the near term. At $2.28, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.37. If the price goes on to break the first support level at $1.96, it is likely to go to the next support level at $1.87. The third support level lies at $1.76 if the price breaches the second support level.

Allogene Therapeutics Inc (NASDAQ: ALLO) Key Stats

There are currently 209,672K shares outstanding in the company with a market cap of 429.83 million. Presently, the company’s annual sales total 100 K according to its annual income of -327,270 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -66,360 K.